» Articles » PMID: 23258801

Immunosenescence-associated MicroRNAs in Age and Heart Failure

Overview
Publisher Wiley
Date 2012 Dec 22
PMID 23258801
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Ageing of the immune system, immunosenescence, is characterized by impaired lymphopoiesis, especially B-lymphocyte maturation, and is a hallmark of chronic heart failure (CHF). MicroRNAs (miRNAs) are non-coding, small RNAs, which post-transcriptionally control gene expression of multiple target genes. The miR-181 family is known to control haematopoietic lineage differentiation. Here, we study the role of the miR-181 family in immunosenescence and CHF.

Methods And Results: We conducted a clinical study analysing peripheral blood (PB) for miRNA expression and leucocyte distribution of young healthy controls (25 ± 4 years; n = 30), aged healthy controls (64 ± 5 years; n = 13), and age-matched CHF patients (64 ± 11years; n = 18). The expression of miR-181 family members was reduced, whereas miR-34a was increased in PB of aged individuals. In particular, miR-181c was further reduced in age-matched CHF patients. In PB, we observed reduced numbers of lymphocytes, in particular cytotoxic T cells and B cells, with rising age, and the expression of miR-181 correlated with the number of B cells. Notably, in CHF patients, ischaemic heart failure was associated with a further reduction of total B cells as well as their subpopulations, such as memory B cells, compared with age-matched healthy volunteers.

Conclusions: Ageing- and CHF-associated changes in PB leucocyte subsets are paralleled by alterations in the expression of miRNAs involved in lymphopoiesis, which might play an important role in the age-related and CHF-mediated dysregulation of immune functions resulting in immunosenescence. Furthermore, miR-181c may serve as a marker for reduced immune functions in CHF patients.

Citing Articles

Single-Cell and Bulk Transcriptomics Reveal the Immunosenescence Signature for Prognosis and Immunotherapy in Lung Cancer.

Zhang Y, Zhou J, Jin Y, Liu C, Zhou H, Sun Y Cancers (Basel). 2025; 17(1.

PMID: 39796714 PMC: 11720133. DOI: 10.3390/cancers17010085.


MicroRNA-181 in cardiovascular disease: Emerging biomarkers and therapeutic targets.

Lv B, He S, Li P, Jiang S, Li D, Lin J FASEB J. 2024; 38(9):e23635.

PMID: 38690685 PMC: 11068116. DOI: 10.1096/fj.202400306R.


Senescent T Cells in Age-Related Diseases.

Yu P, Zhou M, Liu Y, Du J Aging Dis. 2024; .

PMID: 38502582 PMC: 11745454. DOI: 10.14336/AD.2024.0219.


The miR-181 family: Wide-ranging pathophysiological effects on cell fate and function.

Bell-Hensley A, Das S, McAlinden A J Cell Physiol. 2023; 238(4):698-713.

PMID: 36780342 PMC: 10121854. DOI: 10.1002/jcp.30969.


A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research.

Brown C, Mantzaris M, Nicolaou E, Karanasiou G, Papageorgiou E, Curigliano G Cardiooncology. 2022; 8(1):16.

PMID: 36071532 PMC: 9450324. DOI: 10.1186/s40959-022-00142-1.